Open AccessBrief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
Author(s) -
JeanMichel Molina,
Yazdan Yazdanpanah,
Abdulnaser Saud,
Christopher Bettacchi,
C. Chahin Anania,
Stephanie O. Klopfer,
Anjana Grandhi,
Karen Eves,
Deborah A. Hepler,
Michael Robertson,
Carey Hwang,
George J. Hanna,
Todd Correll
Publication year - 2021
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002879
Subject(s) - lamivudine , medicine , adverse effect , reverse transcriptase inhibitor , confidence interval , randomized controlled trial , human immunodeficiency virus (hiv) , sida , virology , viral disease , virus , hepatitis b virus